According to my calculations (in pre-consol terms):
40,000,000 shares @ 0.039 cps = $1560.
(i.e. 0 039 was the issue price of the loan funded shares which equals $0.78 in the new).
Neat trick for RT. Assume a buy back price of $3.
If he paid out the loan his nominal profit would be (2,000,000 * 3) - 1560 = 4,440,000
If the company buys back pro-rata shares to pay out the loan, guess what, it is still the same.
2,000,000 minus the 520,000 bought back equals 1,480,000 left @ $3 equals $4,440,000.
So RT retains the same nett worth without having to put up any funds.
Perhaps not so neat a trick for the company. Talking in the new. They are buying back (an expense) 520,000 shares @ $3 per share ($1,560,000). They issued (income) those same shares for $0.78 each.($405,600). A nominal loss of $1,154,400. (Of course this CASH loss for the company entails a reduction of 520,000 book shares.)
Not a great trade IMO. [In % terms sorta mirrors many of mine].
Another way of looking at it (which gives the same answer) goes like this.
Scenario A: Company issues 2m loan funded shares @ $0.78, which when converted brings in $1.56m.
Scenario B: Company issues 1.48m loan funded shares, which when converted brings in $0. (i.e. the .52m loan funded shares not converted have cost the company $1.56m in revenue or $3 per share.
Under A, any non converted shares will cost the company $0.78 per share in revenue, whilst under B they will cost the company $3 in revenue. Therefore, .52m non converted shares will cost the company a difference of $2.22 per share with A compared to B. ($1,154,00). Same answer as above.
Summary: RT comes out square in nett terms but does not have to provide funds to repay the loan, company loses $1.56m cash benefit whilst shareholders gain approx 0.5% less dilution.
Perhaps I should have just provided the summary, because now my head hurts.
- Forums
- ASX - By Stock
- NEU
- Ann: Notice of Annual General Meeting/Proxy Form
NEU
neuren pharmaceuticals limited
Add to My Watchlist
0.00%
!
$12.85

Ann: Notice of Annual General Meeting/Proxy Form, page-63
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$12.85 |
Change
0.000(0.00%) |
Mkt cap ! $1.598B |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 16 | $14.07 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.07 | 1 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 259 | 13.630 |
1 | 12 | 13.500 |
4 | 727 | 13.490 |
1 | 2 | 13.240 |
1 | 1 | 13.050 |
Price($) | Vol. | No. |
---|---|---|
12.220 | 79 | 2 |
12.480 | 38 | 1 |
12.710 | 705 | 1 |
12.850 | 944 | 3 |
12.860 | 174 | 1 |
Last trade - 09.42am 18/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
Day chart unavailable
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online